Platinum
Platinum is a chemical element whose coordination complexes have an established role in anticancer therapy.
Platinum is a chemical element whose coordination complexes have an established role in anticancer therapy. In oncology, “platinum” commonly refers to platinum-based chemotherapy, including cisplatin, carboplatin, and oxaliplatin. These agents form platinum–DNA adducts that disrupt DNA replication and transcription, producing DNA damage and, in susceptible cancer cells, apoptotic cell death. Platinum therapy is used across several malignancies, including ovarian cancer, lung cancer, breast cancer, and stomach cancer, and may be administered with other chemotherapy, radiation therapy, or immunotherapy.
The therapeutic value of platinum compounds is limited by toxicity, acquired or intrinsic resistance, and incomplete selectivity for cancer cells. Current research is therefore extending platinum therapy through redesigned Pt(II) complexes, drug-delivery systems, catalytic nanoparticles, and combination treatments intended to enhance cytotoxicity or overcome resistance. The supplied literature is concentrated on platinum therapy resistance, targeted cancer treatment strategies, and nanomedicine for cancer therapy, with particular attention to DNA-damage responses, RNA metabolism, tumor microenvironmental effects, and treatment selection in genetically defined cancers.
Rebuilt from PubMed 18 Sept 2026 · no new papers today
Where the papers sit
13 papers study platinum directly. The themes below are drawn from those 13. 1 paradigm shift and 1 new direction follow.
-
Cancer Chemotherapy Outcomes : Mechanism-guided work is targeting platinum resistance through CDK12/13 inhibition and MSH6-linked biology, while other studies track liver ageing, mutational signatures and survival after chemotherapy. BRCA1/2 status remains central to treatment selection. 6 papers · 46.2%
-
Lung Cancer Multimodal Therapy : Platinum treatment is being combined with immunotherapy, radiotherapy, gene editing or nanocarriers to improve lung-cancer control. ROS-driven apoptosis, cancer-stem-cell targeting and survival outcomes recur across these approaches. 5 papers · 38.5%
-
Nanomedicine for Cancer Therapy : Engineered nanoparticles are being used to deliver or activate anticancer agents, with emphasis on cisplatin release, catalytic effects, nitric oxide generation and immune stimulation. 2 papers · 15.4%
Platinum exposure is a source of durable genomic injury, not only a means of treating cancer
Platinum chemotherapy in children treated for cancer and therapy-related subsequent neoplasms in childhood-cancer survivors show that platinum has consequences extending beyond its immediate antitumor use: it is associated with mutations, liver aging, and platinum-correlated NF2 splice-site variants in later meningiomas 42721257Sep 42001506Apr. The assumption that platinum can be treated primarily as an acute anticancer exposure therefore gives way to a model in which it also contributes to long-term tissue aging and genomic risk, with implications for survivorship monitoring and prevention.
Platinum is used as a catalytic nanozyme for antibacterial and tumor therapy
Pt-based nanozymes in porous silica nanoflowers use platinum particle size to optimize peroxidase-like catalysis, bactericidal activity, and cascade tumor therapy with β-lapachone 42328814Jun. Unlike the other papers’ use of platinum as a chemotherapeutic, resistance-related exposure, carrier payload, or treatment sensitizer, this study assigns platinum an enzymelike catalytic role that directly generates therapeutic activity.
Recent Findings on platinum
Platinum Resistance in Cancer: Platinum-based drugs caused mutations and liver aging in children, while platinum therapy correlated with NF2 splice-site variants in subsequent meningiomas 42721257Sep42001506Apr. CDK12/CDK13 inhibition restored platinum cytotoxicity by reshaping RNA processing, alternative splicing, and DNA damage repair in epithelial ovarian cancer models 42686681Sep. Enhancer-associated MSH6 downregulation linked platinum resistance with prognosis and immune features in ovarian cancer 41911956Mar. By contrast, platinum use did not improve outcomes among patients with triple-negative breast cancer carrying germline BRCA1/2 pathogenic variants 42580099Aug. PtNC/SiO2 cluster nanozymes added a catalytic direction, optimizing peroxidase-like activity and β-lapachone-mediated cascade tumor therapy 42328814Jun.
Lung Cancer Platinum Therapy: Pt(II) complexes, durvalumab-etoposide-platinum, and the HAEPRC platform combine platinum activity with stability, immune activation, or radiosensitization. Ligand stabilization improved Pt(II) solution stability, intracellular platinum accumulation, nuclear localization, and activity against gastric cancer stem-like cells through effects on stemness and epithelial-to-mesenchymal transition programs 42720472Sep. In EGFR-mutated advanced non-small cell lung cancer with neuroendocrine transformation, durvalumab plus etoposide-platinum produced a 43% objective response rate, but median progression-free survival was 4.2 months and grade ≥3 adverse events affected 64% of patients 42361644Jun. HAEPRC combined a gold, bismuth, platinum, silver, and palladium high-entropy alloy with CRISPR/Cas9, tumor cell membranes, and Pd-mediated bioorthogonal catalysis to enhance radioimmunotherapy and the abscopal immune effect 41914367Mar.
Nanoparticle Platinum Delivery: Inhalable and mesoporous CuO platforms pair platinum therapeutics with controlled release, tumor targeting, or nitric oxide-mediated immune effects. The inhalable 10m@FOMs-Cu nanogenerator enabled redox-triggered self-catalytic nitric oxide release, Pt(II)-mediated nuclear damage, Cu(II)/Cu(I)-mediated cuproptosis, and durable immune responses in lung adenocarcinoma models 42714559Sep. Mangrove-derived CuO nanoparticles carried cisplatin and oxaliplatin, producing sustained diffusion-governed release and supporting an environmentally friendly platinum drug-delivery strategy 42711436Sep.
Written from 13 PubMed abstracts, each one cited by PMID above. Published: 2026-09-11. Last written: 2026-09-12 by GPT. Drafted by language models from published abstracts; not medical advice.